Abel Hall LLC
BBIO icon

Abel Hall LLC’s BridgeBio Pharma BBIO Stock Holding History

Abel Hall LLC’s Portfolio BBIO Stock Details BBIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$320K Sell
4,861
-1,758
-27% -$137K 0.06% 419
2026
Q2 		$493K Buy
6,619
+1,533
+30% +$107K 0.09% 248
2026
Q1 		$378K Sell
5,086
-5,485
-52% -$398K 0.08% 307
2025
Q4 		$809K Buy
+10,571
New +$694K 0.19% 83

Other funds holding BBIO

Tema ETFs
Tema ETFs New York $2.69B AUM 42.96% 1-Year Est. Return
China Universal Asset Management Company
China Universal Asset Management Company Shanghai, China $1.92B AUM 74.14% 1-Year Est. Return
DekaBank Deutsche Girozentrale
DekaBank Deutsche Girozentrale Frankfurt, Germany $87.8B AUM 20.94% 1-Year Est. Return
Vontobel Holding
Vontobel Holding Zurich, Switzerland $27.7B AUM 21.75% 1-Year Est. Return
AssetMark Inc
AssetMark Inc Concord, California $59.5B AUM 15.92% 1-Year Est. Return
Profund Advisors
Profund Advisors Bethesda, Maryland $3.48B AUM 66.96% 1-Year Est. Return
Burney Company
Burney Company Reston, Virginia $3.66B AUM 27.59% 1-Year Est. Return
Mirae Asset Global Investments
Mirae Asset Global Investments Seoul, South Korea $57B AUM 43.56% 1-Year Est. Return
Caitong International Asset Management
Caitong International Asset Management Hong Kong $1.04B AUM 150.25% 1-Year Est. Return
Oppenheimer Asset Management
Oppenheimer Asset Management New York $9.5B AUM 23.46% 1-Year Est. Return

Abel Hall LLC's BBIO Position: Q3 2026 in Review

Abel Hall LLC reduced its BridgeBio Pharma (BBIO) stake by 27% in Q3 2026, selling an estimated $137K and leaving 4,861 shares worth $320K. The position accounts for 0.06% of the portfolio, ranked #419.

Abel Hall LLC first reported a position in BBIO in Q4 2025 and has held it in 4 quarters since. The position peaked at $809K in Q4 2025. 98 funds tracked by Wall St. Rank hold BBIO as of Q3 2026.

  • Abel Hall LLC held 4,861 shares of BridgeBio Pharma worth $320K as of Q3 2026.
  • Abel Hall LLC sold 1,758 BridgeBio Pharma shares in Q3 2026, an estimated $137K.
  • BridgeBio Pharma made up 0.06% of Abel Hall LLC's portfolio in Q3 2026, its #419 holding.
  • Abel Hall LLC first reported a position in BridgeBio Pharma in Q4 2025 and has held it in 4 quarters since.
  • Abel Hall LLC's BridgeBio Pharma position peaked at $809K in Q4 2025.
  • 98 funds tracked by Wall St. Rank held BridgeBio Pharma as of Q3 2026.

Based on Abel Hall LLC's 13F filing for Q3 2026, filed 19 Oct 2026.